Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT819 + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
FT819 + cyclophosphamide is an investigational combination regimen consisting of FT819, an off-the-shelf, induced pluripotent stem cell (iPSC)-derived, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, and cyclophosphamide, a small-molecule alkylating chemotherapy used as a lymphodepleting conditioning agent. Developed by Fate Therapeutics, this fludarabine-free regimen is designed to deplete disease-causing CD19-positive B cells and allow a healthy immune system to rebuild. It is primarily being evaluated in a Phase 1 clinical trial (NCT06308978) for the treatment of moderate-to-severe B-cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis, systemic sclerosis, idiopathic inflammatory myositis, and ANCA-associated vasculitis.
- Other names
- FT-819 + cyclophosphamideFT-819 plus cyclophosphamideFT819 plus cyclophosphamideFT 819 plus cyclophosphamide
Beyond the preview
Go deeper on FT819 + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT819 + cyclophosphamide.